My previous post was a bit rushed and off the cuff during a...

My previous post was a bit rushed and off the cuff during a moment frustrated about something else. I did not mean to imply that we have wasted the funds from the previous placement if that is how it sounded, i was really just reflecting on the facts which seem to be that our current financial situation is a little precarious considering we have so far only reached end of phase 1 of our stated target of sepsis. And this is without any approach or costs involved in any USA FDA approval. I still think management have done a great job to get us to where we are with still relatively low shares on issue, and it is fairly apparent that they are certainly open to "Pivoting" wherever they see an opportunity that might offer better path to approval, such as the new UTI targets. I guess this simply reinforces what many said early on about the real cost of getting drugs through all phases of testing and to market.

Hopefully the company can come out with some new demonstration of efficacy in any one of the many current targets that will bring back the excitement of the biotech investors and get the shareprice back towards the dollar mark at least. Even at current price i guess they still have the opportunity to raise a significant amount for relatively low shares issue assuming they can find or generate interest from new or existing big Bio investors. Good luck Recce on the upcoming trials and heres hoping we can find another trigger like we did with anti viral announcements right as covid broke before previous raise. Surely if we can demonstrate actual treatment of drug resistant infection in a clinical trial environment that will cause some excitement?